Oxford BioDynamics Plc (LON:OBD – Get Free Report) shares rose 2.2% on Monday . The stock traded as high as GBX 0.16 and last traded at GBX 0.14. 34,958,953 shares traded hands during trading, an increase of 140% from the average daily volume of 14,572,708 shares. The stock had previously closed at GBX 0.14.
Oxford BioDynamics Stock Performance
The stock has a market capitalization of £6.05 million, a P/E ratio of -0.18 and a beta of 0.42. The company’s fifty day simple moving average is GBX 0.19 and its 200 day simple moving average is GBX 0.23. The company has a current ratio of 0.88, a quick ratio of 2.80 and a debt-to-equity ratio of 457.97.
Oxford BioDynamics Company Profile
Its flagship product is EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022.
In March 2021, the Company launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit.
Featured Stories
- Five stocks we like better than Oxford BioDynamics
- The AI Boom Has a Second Act—And It’s Playing Out in Optics
- Gold’s 2026 Rally Has Cracked—Is It Time to Buy the Pullback?
- 5 Tech Stocks to Buy on the July Pullback
- Is OpenAI’s IPO Delay a Warning for AI Investors?
Receive News & Ratings for Oxford BioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.
